Funding for this research was provided by:
Universität Duisburg-Essen
Article History
Accepted: 28 February 2021
First Online: 18 March 2021
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL.
: The authors declare that they have no conflict of interest related to this letter, except that they themselves had carried out two reviews about the highly debated topic of pregabalin´s and gabapentin´s harms and addiction [CitationRef removed, CitationRef removed]. Furthermore, Norbert Scherbaum received honoraria for several activities (advisory boards, lectures, manuscripts) from AbbVie, Camurus, Hexal, Janssen-Cilag, MSD, Medice, Mundipharma, Reckitt-Benckiser/Indivior, and Sanofi-Aventis. During the last 3 years he participated in clinical trials financed by the pharmaceutical industry.